Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 27, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 766,225 Ordinary Shares of 25 pence each.
- Purchase Date: November 27, 2012.
- Price Range: Highest price paid was 1,343.5 pence per share; lowest price paid was 1,334.5 pence per share.
- Treasury Holdings: 490,140,427 shares held in Treasury (9.08% of total issued share capital).
- Voting Rights Impact: Including unsettled purchases, Treasury shares represent 9.98% of total voting rights.
- Shares in Issue: 4,910,347,356 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 766,225 newly purchased shares. This action increases the proportion of shares held in Treasury relative to the total issued capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share repurchase in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (4,910,347,356) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current Treasury share count (490,140,427) and its percentage of total voting rights (9.98% including unsettled trades).
- Review the price paid per share (1,334.5 to 1,343.5 pence) against market prices on November 27, 2012.
- Note that the filing does not contain financial performance data; refer to the most recent Form 20-F or interim reports for revenue and earnings.